Tag: Payor Engagement
BaseCase Interactive for Medical Affairs
How COVID-19 Affects Stakeholder Engagement & Value Communication
By Tom Hemy The COVID-19 pandemic has made the development and commercialization of pharmaceuticals and medical devices even more challenging. For example, in the value communication and stakeholder engagement area, many field representatives found themselves refused entry to hospitals and surgeries and unable to meet in-person with payers, doctors, and other key stakeholders. These meetings … Continued
BaseCase Market Access
The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal
The Market Access Radar (Series)
Evidence & Access – Google Podcasts (Ep. 1-3) Welcome to the Market Access Radar Podcast, your expert briefing on the latest in Market Access and Health Economics in the Bio-Pharmaceutical Industries.
Formulary Decision Making: Must Have Instruments in Value Translation
Innovative contracts are helpful in navigating an evolving pharma marketplace while providing new approaches to distributing life-saving treatments to patients.
Prescription Drug Pricing: “The Times They Are A-Changin”
“Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled” Bob Dylan recorded his iconic “The Times They Are a Changin’” in 1963; the song was released on the 1964 album by the same name. One of … Continued
Rare Diseases: Bridging the Gap between Drug Manufacturers and Payers
High prices for drugs for rare diseases have introduced uncertainties from payers around whether a medication’s value justifies its price.
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported Price Increases.”